PBH Prestige Consumer Healthcare Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1295947 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.1%
TTM net income YoY-22.8%
TTM EPS YoY-19.8%
Revenue 3-yr CAGR1.2%
Net income 3-yr CAGR—
Margins
Gross margin52.5%
Operating margin25.0%
Net margin13.3%
FCF margin18.4%
EBITDA margin28.1%
Returns
ROE8.2%
ROA3.8%
ROIC (approx.)6.9%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets58.8%
Debt / equity1.07x
Current ratio2.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.48x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $336.31M | $265.71M | $281.62M | $283.44M | $274.11M | $249.53M | $296.52M | $290.32M |
| Cost of revenue | $163.77M | $129.52M | $135.32M | $126.08M | $122.53M | $109.20M | $126.51M | $129.27M |
| Gross profit | $172.54M | $136.19M | $146.30M | $157.37M | $151.58M | $140.33M | $170.01M | $161.05M |
| SG&A expense | $30.89M | $43.30M | $30.28M | $29.67M | $28.04M | $28.46M | $27.05M | $26.18M |
| Operating income | $80.71M | $52.52M | $75.49M | $82.49M | $79.67M | $71.76M | $88.43M | $91.96M |
| Interest expense | — | — | — | — | — | — | -$35.07M | $11.46M |
| Income tax | $22.16M | $9.36M | $10.84M | $15.12M | $26.92M | $14.31M | $23.83M | $19.12M |
| Net income | $25.30M | $29.18M | $53.93M | $46.70M | $42.21M | $47.47M | $50.13M | $61.03M |
| EBITDA | $92.68M | $61.27M | $83.84M | $90.08M | $87.33M | $79.42M | $95.68M | $98.83M |
| EPS (basic) | 0.53 | 0.61 | — | 0.98 | 0.86 | 0.96 | — | 1.23 |
| EPS (diluted) | 0.53 | 0.61 | — | 0.97 | 0.86 | 0.95 | — | 1.22 |
| Weighted avg. shares (diluted) | 47.59M | 47.60M | — | 48.09M | 49.26M | 49.83M | — | 49.99M |
| Banking | ||||||||
| Net interest income | -$30.03M | — | -$11.43M | -$10.67M | -$10.04M | -$10.20M | -$10.76M | -$11.46M |
| Provision for credit losses | — | — | $0 | — | — | — | $0 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $46.52M | $89.13M | $63.87M | $62.37M | $119.11M | $139.50M | $97.88M | $50.87M |
| Receivables | $244.12M | $187.35M | $191.92M | $190.46M | $199.00M | $168.41M | $194.29M | $167.27M |
| Inventory | $179.20M | $190.22M | $159.13M | $163.59M | $159.00M | $153.13M | $147.71M | $151.52M |
| Current assets | $492.13M | $496.81M | $431.48M | $433.43M | $497.41M | $480.52M | $448.33M | $377.16M |
| PP&E, net | $116.87M | $117.18M | $121.69M | $128.21M | $73.10M | $73.79M | $74.55M | $73.52M |
| Goodwill | $705.26M | $650.79M | $581.11M | $581.25M | $528.41M | $528.31M | $527.42M | $527.22M |
| Intangibles | $3.36B | $3.24B | $2.30B | $2.30B | $2.29B | $2.29B | $2.30B | $2.31B |
| Total assets | $4.72B | $4.57B | $3.49B | $3.49B | $3.44B | $3.43B | $3.40B | $3.33B |
| Current liabilities | $168.50M | $153.81M | $120.92M | $139.56M | $134.60M | $109.67M | $106.62M | $102.55M |
| Short-term debt | — | $10.45M | $0 | — | — | — | — | — |
| Long-term debt | $2.08B | $2.01B | $993.95M | $1.03B | $993.15M | $992.75M | $992.36M | $1.00B |
| Total debt | $2.08B | $2.02B | $993.95M | $1.03B | $993.15M | $992.75M | $992.36M | $1.00B |
| Total liabilities | $2.78B | $2.65B | $1.61B | $1.67B | $1.62B | $1.58B | $1.57B | $1.54B |
| Shareholders' equity | $1.94B | $1.92B | $1.89B | $1.83B | $1.82B | $1.86B | $1.83B | $1.79B |
| Net debt | $2.03B | $1.93B | $930.09M | $971.17M | $874.04M | $853.25M | $894.47M | $949.13M |
| Cash flow statement | ||||||||
| Operating cash flow | $37.87M | $70.79M | $42.84M | $78.29M | $57.49M | $79.01M | $61.85M | $65.09M |
| Capital expenditure | $3.62M | $3.70M | $5.21M | $3.03M | $2.10M | $838,000 | $3.48M | $1.57M |
| Free cash flow | $34.24M | $67.08M | $37.63M | $75.26M | $55.38M | $78.17M | $58.37M | $63.52M |
| Investing cash flow | -$138.90M | -$1.06B | -$3.41M | -$128.56M | -$2.93M | -$1.94M | -$3.48M | -$9.82M |
| Financing cash flow | $58.30M | $1.02B | -$38.10M | -$6.73M | -$74.95M | -$36.28M | -$11.49M | -$53.87M |
| Depreciation & amortization | $11.96M | $8.75M | $8.35M | $7.59M | $7.66M | $7.67M | $7.25M | $6.87M |
| Stock-based compensation | $1.23M | $3.99M | $2.65M | $2.74M | $1.77M | $3.68M | $2.73M | $2.87M |
| Share buybacks | $0 | $0 | $690,000 | $45.82M | $75.00M | $34.77M | $11.31M | $2.40M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.